Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

<table>Representative chromatograms of somatic mutations (sense 5′) of (a): HER2 Exon 20 Q795R; (b): HER2 Exon 20 W825X (Stop); (c): HER2 Exon 20 Y781C; (d) EGFR Exon 21, R836R, and V843I.</table>

Journal of Oncology

fig2

Figure 2

Figure 2: Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study 

Figure 2 | Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study 